IJTLD open最新文献_第2页

Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TB. 贝达喹啉、利奈唑胺、氯法齐明“核心”治疗耐多药结核病的有效性。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.24.0515

C Zeng, M A Hernán, L Trevisi, S Sauer, C D Mitnick, C Hewison, M Bastard, P Khan, K J Seung, M L Rich, S Law, M Kikvidze, O Kirakosyan, A Miankou, P Thit, S Mamsa, A Janmohamed, N Melikyan, S Ahmed, D Vargas, A B Binegdie, K Temirova, L Oyewusi, K Philippe, S C Vilbrun, U Khan, H Huerga, M F Franke

{"title":"Effectiveness of a bedaquiline, linezolid, clofazimine 'core' for multidrug-resistant TB.","authors":"C Zeng, M A Hernán, L Trevisi, S Sauer, C D Mitnick, C Hewison, M Bastard, P Khan, K J Seung, M L Rich, S Law, M Kikvidze, O Kirakosyan, A Miankou, P Thit, S Mamsa, A Janmohamed, N Melikyan, S Ahmed, D Vargas, A B Binegdie, K Temirova, L Oyewusi, K Philippe, S C Vilbrun, U Khan, H Huerga, M F Franke","doi":"10.5588/ijtldopen.24.0515","DOIUrl":"10.5588/ijtldopen.24.0515","url":null,"abstract":"Background: Treatment outcomes may be compromised among individuals with multidrug/rifampicin-resistant TB (MDR/RR-TB) with fluoroquinolone (FQ) resistance. Among people in whom an FQ was unlikely to be effective, we compared the effectiveness of longer individualised regimens comprised of bedaquiline (Bdq) for 5-8 months, linezolid, and clofazimine to those reinforced with at least 1 Group C drug and/or longer Bdq duration.Methods: We emulated a target trial to compare the effectiveness of initiating and remaining on the core regimen to a regimen reinforced with 1) Bdq for ≥9 months, 2) Bdq for ≥9 months, and delamanid (Dlm), 3) imipenem (Imp), 4) a second-line injectable, or 5) Bdq for ≥9 months, Dlm and Imp. We used cloning, censoring, and inverse-probability weighting to estimate the probabilities of successful treatment.Results: Adjusted probabilities of successful treatment ranged from 0.75 (95% CI 0.61-0.89) to 0.84 (95% CI 0.76-0.91). Ratios of treatment success ranged from 1.01 for regimens reinforced with Bdq ≥9 months (95% CI 0.79-1.28) and Bdq ≥9 months plus Dlm (95% CI 0.81-1.31) to 1.11 for regimens reinforced with an injectable (95% CI 0.92-1.39) and Bdq ≥9 months, Dlm and Imp (95% CI 0.90-1.41).Conclusions: Some reinforced regimens had modestly higher treatment success rates, but estimates were imprecise. Additional studies of strategies for maximising treatment success among individuals with FQ resistance are needed.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 5","pages":"269-275"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144016464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New drugs are not enough: addressing social determinants as a critical component of drug-resistant TB care. 光有新药是不够的：解决社会决定因素是耐药结核病治疗的一个关键组成部分。

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.25.0075

D Giovenco, N S Shah, K Ansorge, D Operario, N R Gandhi

引用次数: 0

Low preventive treatment initiation and completion among young children contacts of active TB in Tbilisi, Georgia. 在格鲁吉亚第比利斯，接触活动性结核病的幼儿开始和完成预防性治疗的比例较低。

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.24.0594

E Kokhreidze, R R Kempker, N Tukvadze, M C Schechter, Z Avaliani, H M Blumberg, M Butsashvili, N Lomtadze

{"title":"Low preventive treatment initiation and completion among young children contacts of active TB in Tbilisi, Georgia.","authors":"E Kokhreidze, R R Kempker, N Tukvadze, M C Schechter, Z Avaliani, H M Blumberg, M Butsashvili, N Lomtadze","doi":"10.5588/ijtldopen.24.0594","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0594","url":null,"abstract":"Background: Within the Georgian National Tuberculosis Program (NTP), TB preventive treatment (TPT) is recommended for all child TB contacts ≤5 years. To assess adherence to this guidance, we evaluated the care cascade for the treatment of latent TB infection among children ≤5 years at the National Center for Tuberculosis and Lung Disease (NCTLD).Methods: We performed a cohort study among children ≤5 years evaluated at NCTLD during 2012-2014 as a contact of active pulmonary TB people. We recorded how many patients were recommended to start isoniazid preventive therapy (IPT) and how many initiated and completed treatment.Results: Among 172 contacts of active TB people who visited the NCTLD between 2012 and 2014, 134 (74%) were contacts to drug-susceptible TB index cases. Among children recommended to start IPT (n= 94), 50 (51%) initiated treatment, and 16 (33%) completed IPT. Overall, 4 (4%) contacts developed active TB during 1,483 person-years of follow-up (mean 8.6 years), including 1 in the IPT group who did not complete therapy and 3 (6%) in the non-IPT group.Conclusions: Our findings highlight low rates of LTBI treatment recommendation, TPT initiation and completion among young children who were TB contacts in Georgia, highlighting the need for improved monitoring and enhanced treatment programs and regimens.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 4","pages":"230-234"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB. 耐药肺结核疗效和治疗效果的15年趋势。

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.24.0620

M J Nasiri, M Amiri, M Cheraghi, D R Silva, G Sotgiu, L D'Ambrosio, R Centis, M Mileva-Lopez, T M Hill, S Gidey, K Diaby, N Hittel, H Gandhi, M Dara

{"title":"15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB.","authors":"M J Nasiri, M Amiri, M Cheraghi, D R Silva, G Sotgiu, L D'Ambrosio, R Centis, M Mileva-Lopez, T M Hill, S Gidey, K Diaby, N Hittel, H Gandhi, M Dara","doi":"10.5588/ijtldopen.24.0620","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0620","url":null,"abstract":"Background: This study describes the evolution of treatment outcomes in drug-resistant (DR) pulmonary TB, focusing on efficacy and effectiveness.Methods: We searched PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science reporting DR-TB regimens from 1 January 2009 to 8 May 2024 and performed a systematic literature review and meta-analysis.Results: A gradual increase in success rates in the treatment of DR pulmonary TB was observed from 2009 to 2024 across all studies. In observational studies, the average treatment success rate for mono-resistant TB (non-rifampicin-resistant TB, RR-TB) was 82.9%, while the average treatment success rate for RR/multidrug-resistant TB (MDR-TB) was 68.4%, and that of pre-extensively drug-resistant TB (pre-XDR-TB) and XDR-TB was 54.4% with an increasing trend over time. The outcomes of experimental studies, which included fewer patients, demonstrated 69.6% treatment success for RR/MDR-TB, with higher rates for pre-XDR/XDR-TB (79.2%) and a mix of the two groups (85.8%). Significant geographic variations in outcome rates were observed across studies.Conclusion: The current study demonstrates a steady improvement in treatment outcomes for DR-TB after a long period of stagnation. However, new drugs and novel regimens are needed to maintain or further improve treatment outcomes in DR-TB.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 4","pages":"187-198"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of US funding cuts and stop work orders on TB services and research in South Africa. 美国削减资助和停止工作令对南非结核病服务和研究的影响。

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.25.0168

N Ndjeka, M Kubjane, F Abdullah, E Mohr-Holland, P Subrayen, M Loveday, M Dube, J Boffa

引用次数: 0

Impact of helminth co-infection and treatment on mycobacterial growth inhibition in UK migrants with TB infection. 寄生虫共感染和治疗对结核感染英国移民分枝杆菌生长抑制的影响。

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.24.0528

S Anwar, C F Turienzo, L Tsang, S G Smith, H Fletcher, F Toulza, J M Cliff, M Brown, H M Dockrell

{"title":"Impact of helminth co-infection and treatment on mycobacterial growth inhibition in UK migrants with TB infection.","authors":"S Anwar, C F Turienzo, L Tsang, S G Smith, H Fletcher, F Toulza, J M Cliff, M Brown, H M Dockrell","doi":"10.5588/ijtldopen.24.0528","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0528","url":null,"abstract":"Background: TB and helminth infections are co-endemic in many parts of the world. This has led to the hypothesis that immunomodulation due to helminth infections could adversely affect the ability to control Mycobacterium tuberculosis infection. Anti-helminthic treatment has been associated with improved anti-mycobacterial cellular responses and decreases in the frequency of regulatory T-cells. We therefore investigated how control of mycobacterial growth and anti-mycobacterial immune responses are modulated in helminth and TB co-infected individuals using a mycobacterial growth inhibition assay (MGIA).Methods: Migrants with eosinophilia or suspected/diagnosed helminth infection and/or TB infection (TBI) were recruited when attending University College London Hospitals (London, UK) and followed up after completing anti-helminthic treatment. Mycobacterial growth inhibition was assessed using the BACTEC™ MGIT™ system after 72 hours of co-culture of peripheral blood mononuclear cells (PBMC) with M. bovis bacille Calmette-Guérin (BCG) or M. tuberculosis Erdman.Results: Anti-helminthic treatment reduced total and helminth-specific antibodies in helminth-infected and TBI-helminth co-infected individuals. Helminth-infected individuals displayed lower growth inhibition in the MGIA than those without helminth infections, and mycobacterial growth inhibition improved after anti-helminthic treatment. Blocking interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) improved mycobacterial growth inhibition, while blocking interferon-gamma (IFN-γ) did not alter growth inhibition.Conclusion: Infection with helminths such as Schistosoma mansoni and Strongyloides spp. may reduce the ability to control mycobacterial growth.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 4","pages":"217-223"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incremental yield in detection of TB by testing multiple stool specimens from one person. 通过检测一个人的多个粪便标本来检测结核病的增量产量。

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.24.0605

E Tiemersma, B Yenew, G Diriba, D Jerene, A Bedru, P de Haas

引用次数: 0

Children's preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations. 儿童对六种新型莫西沙星和利奈唑胺分散片的偏好。

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.24.0546

G Hoddinott, H R Draper, N Vanqa, S Myeni, S Staples, T Sachs, M Raffique, N Tshethu, M Palmer, L Viljoen, K Inabathina, R Taneja, A C Hesseling, A J Garcia-Prats

{"title":"Children's preferences among six novel moxifloxacin and linezolid-dispersible tablet formulations.","authors":"G Hoddinott, H R Draper, N Vanqa, S Myeni, S Staples, T Sachs, M Raffique, N Tshethu, M Palmer, L Viljoen, K Inabathina, R Taneja, A C Hesseling, A J Garcia-Prats","doi":"10.5588/ijtldopen.24.0546","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0546","url":null,"abstract":"Background: Moxifloxacin (MFX) and linezolid (LZD) are key components of rifampicin-resistant TB treatment regimens. Currently, available dispersible tablet formulations of both drugs have poor palatability in children. We evaluated children's preferences for more child-friendly formulations from two generic manufacturers.Methods: This was a randomised, cross-sectional 'swish-and-spit' taste panel study at two sites in South Africa. Each manufacturer created three flavour-blend variants for each drug. Healthy child volunteers 5-17 years old were sampled stratified by age, sex, and ethnic group and completed a preference rank-ordering and five acceptability 5-point Likert scales. We explored the blends' acceptability using summary, comparative, and ranking statistics.Results: Ninety-seven and 96 children contributed data for the MFX and LZD drug blends, respectively. For both manufacturers' MFX blends, the Friedman test showed children had a statistically significant preference for novel options over the Existing blend (Q(2) = 24,937; P < 0.001, and Q(2) = 21.213; P < 0.001, respectively). Even the most preferred MFX blend had sub-optimal acceptability, especially for one manufacturer. Children did not have a clear preference for both manufacturers' LZD blends. These findings were not influenced by age, sex, or ethnic group.Conclusion: Children across a broad age spectrum can provide meaningful input on the palatability preferences of TB drug formulations. Novel MFX formulation blends were recommended for development, but acceptability remains suboptimal.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 4","pages":"208-216"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unilateral pulmonary vein atresia. 单侧肺静脉闭锁。

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.24.0631

Y Wang, Y Tang, L Sun, X Zhang, Y Liu, S Xu, Y Su, L Zhang, X Tang, H Yang, Y Shen

{"title":"Unilateral pulmonary vein atresia.","authors":"Y Wang, Y Tang, L Sun, X Zhang, Y Liu, S Xu, Y Su, L Zhang, X Tang, H Yang, Y Shen","doi":"10.5588/ijtldopen.24.0631","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0631","url":null,"abstract":"Objective: This study aims to summarise the clinical characteristics of unilateral pulmonary vein atresia (UPVA) and compare the differences between Chinese cases and all published cases worldwide.Methods: We retrospectively enrolled 6 Chinese children with UPVA from January 2014 to January 2024 at a single centre. We reviewed their demographic data, clinical symptoms, laboratory tests, imaging examinations, treatment and prognosis to describe their clinical features. Additionally, the remaining 79 confirmed patients with UPVA, as described in 52 references, were also summarised.Results: UPVA is sporadically distributed worldwide, with the highest number of reported cases in China (27/85) and the United States (20/85). In the overall cohort (85 cases), the patient median age at diagnosis was 5.2 years. The male-to-female ratio was 1:1. Right-sided UPVA was slightly more common, with a right-to-left ratio of 1.4:1. The most frequently reported clinical manifestations were recurrent pneumonia (79.2%), followed by recurrent haemoptysis (48.1%) and exercise intolerance (35.1%). Additionally, 10.4% of patients were asymptomatic. Congenital heart disease was observed in 34.1% of cases, and 20% of patients had comorbid pulmonary hypertension. The overall mortality rate was 8.9%.Conclusion: There were no statistically significant differences in the clinical characteristics of UPVA between Chinese patients and all published cases worldwide.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 4","pages":"224-229"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary TB. Truenat™MTB Plus诊断肺结核的准确性

IJTLD open Pub Date : 2025-04-09 eCollection Date: 2025-04-01 DOI: 10.5588/ijtldopen.24.0561

M C M Melo, A K Silveira, A P R Dalvi, J Silva, V S Printes, L Anselmo, T I da Silva, M M Oliveira, C Conceição, A Lopes, V Bollela, M Cordeiro-Santos, M Bhering, A S R Moreira, A C C Carvalho, A L Kritski

{"title":"Accuracy of Truenat™ MTB Plus for the diagnosis of pulmonary TB.","authors":"M C M Melo, A K Silveira, A P R Dalvi, J Silva, V S Printes, L Anselmo, T I da Silva, M M Oliveira, C Conceição, A Lopes, V Bollela, M Cordeiro-Santos, M Bhering, A S R Moreira, A C C Carvalho, A L Kritski","doi":"10.5588/ijtldopen.24.0561","DOIUrl":"https://doi.org/10.5588/ijtldopen.24.0561","url":null,"abstract":"Background: Truenat™ is a WHO-recommended rapid molecular test for diagnosing TB and detecting rifampicin resistance, whose performance has been evaluated in a few high TB burden countries.Methods: A prospective multicentre study was conducted in Brazil to estimate the sensitivity and specificity of Truenat MTB Plus compared to Xpert® MTB/RIF Ultra for detecting pulmonary TB. Liquid culture for Mycobacterium tuberculosis and drug susceptibility testing were used as reference.Results: Among 283 participants, 112 (39.6%) had culture-positive pulmonary TB. The sensitivity and specificity of Truenat MTB Plus were respectively 72.7% (95% CI 63.41-80.78) and 99.4% (95% CI 96.71-99.98), compared to 78.4% (95% CI 69.56-85.63) and 99.4% (95% CI 96.67-99.98) for Xpert MTB/RIF Ultra. In 89 people living with HIV (PLHIV), Truenat MTB Plus showed a sensitivity of 45.0% (95% CI 23.06-68.47) and specificity of 100.0% (95% CI 95.64-100.00). Among 71 patients previously treated for TB, Truenat MTB Plus showed sensitivity and specificity of respectively 79.3% (95% CI 60.28-92.01) and 97.5% (95% CI 86.84-99.94). Xpert MTB/RIF Ultra detected rifampicin resistance in 11/88 samples (12.5%) vs 9/72 (12.5%) with Truenat MTB Plus.Conclusion: The Truenat MTB Plus performance was comparable to Xpert MTB/RIF Ultra. Both tests demonstrated lower sensitivity in PLHIV.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 4","pages":"199-207"},"PeriodicalIF":0.0,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11984528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0